-
1.发明授权公开(公告)号：US09128107B2
公开(公告)日：2015-09-08
申请号：US13125631
申请日：2009-10-22
CPC分类号： G01N33/74 , G01N2333/58 , G01N2800/347
摘要： Subject of the present invention are assays and in vitro methods for prediction of the progression of primary chronic kidney disease (CKD) or for monitoring chronic kidney disease therapy comprising the determination of the level of ANP and/or ADM or its precursors or fragments thereof.
摘要翻译： 本发明的主题是用于预测原发性慢性肾脏病（CKD）进展或用于监测慢性肾脏疾病治疗的测定和体外方法，包括测定ANP和/或ADM或其前体或其片段的水平。
-
2.发明申请公开(公告)号：US20120003752A1
公开(公告)日：2012-01-05
申请号：US13125631
申请日：2009-10-22
IPC分类号： G01N33/566
CPC分类号： G01N33/74 , G01N2333/58 , G01N2800/347
摘要： Subject of the present invention are assays and in vitro methods for prediction of the progression of primary chronic kidney disease (CKD) or for monitoring chronic kidney disease therapy comprising the determination of the level of ANP and/or ADM or its precursors or fragments thereof.
摘要翻译： 本发明的主题是用于预测原发性慢性肾脏病（CKD）进展或用于监测慢性肾脏疾病治疗的测定和体外方法，包括测定ANP和/或ADM或其前体或其片段的水平。
-
公开(公告)号：US20120135428A1
公开(公告)日：2012-05-31
申请号：US13280719
申请日：2011-10-25
IPC分类号： G01N33/566 , C07K16/22 , C07K16/26
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/118
摘要： The present invention relates to a method for determining the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.
摘要翻译： 本发明涉及一种用于确定疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，包括确定选自（a）FGF23的至少一种标志物的表达水平; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23或脂联素的特异性检测分子用于制备用于检测疑似患有所述疾病的受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物的用途。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。
-
公开(公告)号：US08058015B2
公开(公告)日：2011-11-15
申请号：US12523625
申请日：2008-01-21
IPC分类号： G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/118
摘要： The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.
摘要翻译： 本发明涉及一种用于确定或预测疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，所述方法包括确定选自（a）的至少一种标志物的表达水平的步骤， FGF23; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23的特异性检测分子的用途或者用于脂联素的特异性检测分子的用途，用于制备用于检测受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物 患有所述疾病。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。
-
公开(公告)号：US08623607B2
公开(公告)日：2014-01-07
申请号：US13280719
申请日：2011-10-25
IPC分类号： G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/118
摘要： The present invention relates to a method for determining or predicting the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.
摘要翻译： 本发明涉及一种用于确定或预测疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，包括确定选自（a）FGF23的至少一种标志物的表达水平; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23或脂联素的特异性检测分子用于制备用于检测疑似患有所述疾病的受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物的用途。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。
-
公开(公告)号：US20100143951A1
公开(公告)日：2010-06-10
申请号：US12523625
申请日：2008-01-21
IPC分类号： G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/118
摘要： The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.
摘要翻译： 本发明涉及一种用于确定或预测疑似患有慢性肾脏疾病的受试者的慢性肾脏疾病进展的方法，所述方法包括确定选自（a）的至少一种标志物的表达水平的步骤， FGF23; 和（b）生物样品中的脂联素。 此外，本发明涉及用于FGF23的特异性检测分子的用途或者用于脂联素的特异性检测分子的用途，用于制备用于检测受试者的慢性肾脏疾病或慢性肾脏疾病进展的诊断组合物 患有所述疾病。 特别地，本发明还提供使用FGF23和/或脂连蛋白作为慢性肾脏疾病的存在，不存在或进展的体外标记物，以及包含用于FGF23的特异性检测分子或脂联素特异性检测分子的试剂盒 用于本发明的方法中。
-
7.发明申请Method for Diagnosing Tumors by Measuring the Level of Apolipoprotein A-IV 审中-公开通过测量载脂蛋白A-IV水平诊断肿瘤的方法公开(公告)号：US20100136583A1
公开(公告)日：2010-06-03
申请号：US12063369
申请日：2006-08-08
IPC分类号： G01N33/574 , G01N33/567 , G01N33/53
CPC分类号： G01N33/92 , G01N33/57411 , G01N33/57438 , G01N33/57449 , G01N2800/52
摘要： Method for diagnosing a tumor in an individual comprising the following steps: —measuring the amount of apolipoprotein A-IV (ApoA-IV) in a body fluid sample or tissue sample of an individual, —comparing the measured amount of ApoA-IV in said sample with a reference value, wherein the reference value is the ApoA-IV content in a sample derived from an individual without a tumor, and —diagnosing a tumor if the ApoA-IV content in the sample is decreased compared to the reference value.
摘要翻译： 用于诊断个体肿瘤的方法，包括以下步骤： - 测定个体的体液样品或组织样品中载脂蛋白A-IV（ApoA-IV）的量， - 比较所述测定的ApoA-IV量 具有参考值的样品，其中参考值是源自没有肿瘤的个体的样品中的ApoA-IV含量，以及如果样品中的ApoA-IV含量与参考值相比降低则诊断肿瘤。
-
公开(公告)号：US20100285463A1
公开(公告)日：2010-11-11
申请号：US12667135
申请日：2008-06-27
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6827 , C12Q2531/149 , C12Q2525/179
摘要： The present invention relates to a method for selecting a DNA sample comprising genomic DNA suitable for genotyping, comprising the steps of: i) pre-genotyping said genomic DNA using a set of polymorphic markers; ii) determining out of said set of polymorphic markers the percentage of polymorphic markers for which said genomic DNA is homozygous; and iii) selecting said DNA sample when said genomic DNA is homozygous for less than 70% of said set of polymorphic markers. Furthermore, a method of genotyping comprising a step of using a DNA sample selected by the method in accordance with the present invention and/or a step of applying the method provided herein is disclosed. The present invention also relates to a method for identifying a gene or a locus on a genome, said method comprising a step of using a DNA sample selected by the method provided herein and a step of applying the method described herein. Further, the present invention relates to a kit for carrying out the method in accordance with the present invention comprising primers for the amplification of the set of polymorphic markers employed herein.
摘要翻译： 本发明涉及一种用于选择包含适合基因分型的基因组DNA的DNA样品的方法，其包括以下步骤：i）使用一组多态性标记对所述基因组DNA进行前基因分型; ii）确定所述多态性标记集合中所述基因组DNA是纯合的多态标志物的百分比; 以及iii）当所述基因组DNA对所述多态性标记物组的少于70％是纯合的时，选择所述DNA样品。 此外，公开了一种基因分型方法，其包括使用根据本发明的方法选择的DNA样品和/或应用本文提供的方法的步骤。 本发明还涉及用于鉴定基因组上的基因或基因座的方法，所述方法包括使用通过本文提供的方法选择的DNA样品的步骤和应用本文所述方法的步骤。 此外，本发明涉及用于实施根据本发明的方法的试剂盒，其包含用于扩增本文使用的多态性标记组的引物。
-
公开(公告)号：US08137922B2
公开(公告)日：2012-03-20
申请号：US12676528
申请日：2008-09-04
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2333/76 , G01N2800/04
摘要： The present invention discloses a method for diagnosing the metabolic syndrome by determination of the afamin content in a sample of a body fluid or a tissue sample, wherein the metabolic syndrome is diagnosed if the afamin content in the sample is increased compared to the afamin content in a sample from a person not having the metabolic syndrome.
摘要翻译： 本发明公开了一种用于通过测定体液或组织样品的样品中的尿素含量来诊断代谢综合征的方法，其中如果样品中的微量蛋白质含量相比于所述代谢综合征中的尿素含量增加，则代谢综合征被诊断 来自不具有代谢综合征的人的样品。
-
公开(公告)号：US07842463B2
公开(公告)日：2010-11-30
申请号：US10485039
申请日：2002-07-23
申请人： Florian Kronenberg
发明人： Florian Kronenberg
CPC分类号： G01N33/6893 , G01N2800/042 , G01N2800/347 , Y10S436/811 , Y10T436/106664
摘要： There is disclosed a method of diagnosing early stage renal impairment in humans, characterized by the following steps: measuring the amount of apoA-IV in a body liquid or tissue sample of a human, and comparing the measured amount of apoA-IV with a reference value.
摘要翻译： 公开了一种诊断人类早期肾损伤的方法，其特征在于以下步骤：测量人体液体或组织样品中apoA-IV的量，并将测定的apoA-IV与参考值 值。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.024 秒)
